[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "Specific outcomes upon activation of the c-Jun N-terminal kinase (JNK) pathway critically depend on the intensity and duration of signal transmission. Dual-specificity phosphatases (DUSPs) play a very important role in these events by modulating the extent of JNK phosphorylation and activation and thus regulating cellular responses to stress. M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK. It has been shown that M3/6 itself is phosphorylated by JNK upon stimulation with arsenite, but the role of this phosphorylation has not been investigated. In this study, we mapped JNK-induced phosphorylation sites on M3/6 using mass spectrometry. Phosphorylated residues Ser 515, Thr 518 and Ser 520 were identified and site-directed mutagenesis was employed to investigate their role. Upon arsenite stimulation, M3/6 mutated at these sites exhibited decreased phosphorylation compared to the wild-type protein. No difference was observed in terms of the enzyme's in vitro phosphatase activity, its substrate specificity towards JNK isoforms, its interactions with JNK and the scaffold family of JNK-interacting proteins (JIPs), its stability or its subcellular localization. Interestingly, expression of M3/6 phosphorylation mutants delayed the time-course of JNK phosphorylation and activation by arsenite. We propose that phosphorylation of the M3/6 phosphatase by JNK in response to stress stimuli results in attenuation of phosphatase activity and acceleration of JNK activation.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "a351b22b820341a499b92892e91315d8", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [112, 112], [77, 77], [192, 192], [186, 186], [198, 198], [226, 226], [89, 89], [242, 242], [14, 14], [257, 257]], "char_spans": [[260, 262], [630, 632], [444, 446], [1115, 1117], [1079, 1081], [1146, 1148], [1311, 1313], [505, 507], [1418, 1420], [66, 68], [1519, 1521]]}]}], "context_tokens": [["Specific", 0], ["outcomes", 9], ["upon", 18], ["activation", 23], ["of", 34], ["the", 37], ["c", 41], ["-", 42], ["Jun", 43], ["N", 47], ["-", 48], ["terminal", 49], ["kinase", 58], ["(", 65], ["JNK", 66], [")", 69], ["pathway", 71], ["critically", 79], ["depend", 90], ["on", 97], ["the", 100], ["intensity", 104], ["and", 114], ["duration", 118], ["of", 127], ["signal", 130], ["transmission", 137], [".", 149], ["Dual", 151], ["-", 155], ["specificity", 156], ["phosphatases", 168], ["(", 181], ["DUSPs", 182], [")", 187], ["play", 189], ["a", 194], ["very", 196], ["important", 201], ["role", 211], ["in", 216], ["these", 219], ["events", 225], ["by", 232], ["modulating", 235], ["the", 246], ["extent", 250], ["of", 257], ["JNK", 260], ["phosphorylation", 264], ["and", 280], ["activation", 284], ["and", 295], ["thus", 299], ["regulating", 304], ["cellular", 315], ["responses", 324], ["to", 334], ["stress", 337], [".", 343], ["M3/6", 345], ["(", 350], ["DUSP8", 351], [")", 356], ["is", 358], ["one", 361], ["of", 365], ["the", 368], ["dual", 372], ["-", 376], ["specificity", 377], ["protein", 389], ["phosphatases", 397], ["with", 410], ["distinct", 415], ["specificity", 424], ["towards", 436], ["JNK", 444], [".", 447], ["It", 449], ["has", 452], ["been", 456], ["shown", 461], ["that", 467], ["M3/6", 472], ["itself", 477], ["is", 484], ["phosphorylated", 487], ["by", 502], ["JNK", 505], ["upon", 509], ["stimulation", 514], ["with", 526], ["arsenite", 531], [",", 539], ["but", 541], ["the", 545], ["role", 549], ["of", 554], ["this", 557], ["phosphorylation", 562], ["has", 578], ["not", 582], ["been", 586], ["investigated", 591], [".", 603], ["In", 605], ["this", 608], ["study", 613], [",", 618], ["we", 620], ["mapped", 623], ["JNK", 630], ["-", 633], ["induced", 634], ["phosphorylation", 642], ["sites", 658], ["on", 664], ["M3/6", 667], ["using", 672], ["mass", 678], ["spectrometry", 683], [".", 695], ["Phosphorylated", 697], ["residues", 712], ["Ser", 721], ["515", 725], [",", 728], ["Thr", 730], ["518", 734], ["and", 738], ["Ser", 742], ["520", 746], ["were", 750], ["identified", 755], ["and", 766], ["site", 770], ["-", 774], ["directed", 775], ["mutagenesis", 784], ["was", 796], ["employed", 800], ["to", 809], ["investigate", 812], ["their", 824], ["role", 830], [".", 834], ["Upon", 836], ["arsenite", 841], ["stimulation", 850], [",", 861], ["M3/6", 863], ["mutated", 868], ["at", 876], ["these", 879], ["sites", 885], ["exhibited", 891], ["decreased", 901], ["phosphorylation", 911], ["compared", 927], ["to", 936], ["the", 939], ["wild", 943], ["-", 947], ["type", 948], ["protein", 953], [".", 960], ["No", 962], ["difference", 965], ["was", 976], ["observed", 980], ["in", 989], ["terms", 992], ["of", 998], ["the", 1001], ["enzyme", 1005], ["'s", 1011], ["in", 1014], ["vitro", 1017], ["phosphatase", 1023], ["activity", 1035], [",", 1043], ["its", 1045], ["substrate", 1049], ["specificity", 1059], ["towards", 1071], ["JNK", 1079], ["isoforms", 1083], [",", 1091], ["its", 1093], ["interactions", 1097], ["with", 1110], ["JNK", 1115], ["and", 1119], ["the", 1123], ["scaffold", 1127], ["family", 1136], ["of", 1143], ["JNK", 1146], ["-", 1149], ["interacting", 1150], ["proteins", 1162], ["(", 1171], ["JIPs", 1172], [")", 1176], [",", 1177], ["its", 1179], ["stability", 1183], ["or", 1193], ["its", 1196], ["subcellular", 1200], ["localization", 1212], [".", 1224], ["Interestingly", 1226], [",", 1239], ["expression", 1241], ["of", 1252], ["M3/6", 1255], ["phosphorylation", 1260], ["mutants", 1276], ["delayed", 1284], ["the", 1292], ["time", 1296], ["-", 1300], ["course", 1301], ["of", 1308], ["JNK", 1311], ["phosphorylation", 1315], ["and", 1331], ["activation", 1335], ["by", 1346], ["arsenite", 1349], [".", 1357], ["We", 1359], ["propose", 1362], ["that", 1370], ["phosphorylation", 1375], ["of", 1391], ["the", 1394], ["M3/6", 1398], ["phosphatase", 1403], ["by", 1415], ["JNK", 1418], ["in", 1422], ["response", 1425], ["to", 1434], ["stress", 1437], ["stimuli", 1444], ["results", 1452], ["in", 1460], ["attenuation", 1463], ["of", 1475], ["phosphatase", 1478], ["activity", 1490], ["and", 1499], ["acceleration", 1503], ["of", 1516], ["JNK", 1519], ["activation", 1523], [".", 1533]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disease. A key pathological feature of PD is Lewy bodies, of which the major protein component is \u03b1-synuclein (\u03b1-syn). Human genetic studies have shown that mutations (A53T, A30P, E46K) and multiplication of the \u03b1-syn gene are linked to familial PD. Mice overexpressing the human A53T mutant \u03b1-syn gene develop severe movement disorders. However, the molecular mechanisms of \u03b1-syn toxicity are not well understood. Recently, mitochondrial dysfunction has been linked with multiple neurodegenerative diseases including Parkinson's disease. Here we investigated whether mitochondrial motility, dynamics and respiratory function are affected in primary neurons from a mouse model expressing the human A53T mutation. We found that mitochondrial motility was selectively inhibited in A53T neurons while transport of other organelles was not affected. In addition, A53T expressing neurons showed impairment in mitochondrial membrane potential and mitochondrial respiratory function. Furthermore, we found that rapamycin, an autophagy inducer, rescued the decreased mitochondrial mobility. Taken together, these data demonstrate that A53T \u03b1-syn impairs mitochondrial function and dynamics and the deficit of mitochondrial transport is reversible, providing further understanding of the disease pathogenesis and a potential therapeutic strategy for PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4687700336544ca7b5e25c199a0d7523", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[31, 33]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disease", 69], [".", 76], ["A", 78], ["key", 80], ["pathological", 84], ["feature", 97], ["of", 105], ["PD", 108], ["is", 111], ["Lewy", 114], ["bodies", 119], [",", 125], ["of", 127], ["which", 130], ["the", 136], ["major", 140], ["protein", 146], ["component", 154], ["is", 164], ["\u03b1", 167], ["-", 168], ["synuclein", 169], ["(", 179], ["\u03b1", 180], ["-", 181], ["syn", 182], [")", 185], [".", 186], ["Human", 188], ["genetic", 194], ["studies", 202], ["have", 210], ["shown", 215], ["that", 221], ["mutations", 226], ["(", 236], ["A53", 237], ["T", 240], [",", 241], ["A30P", 243], [",", 247], ["E46", 249], ["K", 252], [")", 253], ["and", 255], ["multiplication", 259], ["of", 274], ["the", 277], ["\u03b1", 281], ["-", 282], ["syn", 283], ["gene", 287], ["are", 292], ["linked", 296], ["to", 303], ["familial", 306], ["PD", 315], [".", 317], ["Mice", 319], ["overexpressing", 324], ["the", 339], ["human", 343], ["A53", 349], ["T", 352], ["mutant", 354], ["\u03b1", 361], ["-", 362], ["syn", 363], ["gene", 367], ["develop", 372], ["severe", 380], ["movement", 387], ["disorders", 396], [".", 405], ["However", 407], [",", 414], ["the", 416], ["molecular", 420], ["mechanisms", 430], ["of", 441], ["\u03b1", 444], ["-", 445], ["syn", 446], ["toxicity", 450], ["are", 459], ["not", 463], ["well", 467], ["understood", 472], [".", 482], ["Recently", 484], [",", 492], ["mitochondrial", 494], ["dysfunction", 508], ["has", 520], ["been", 524], ["linked", 529], ["with", 536], ["multiple", 541], ["neurodegenerative", 550], ["diseases", 568], ["including", 577], ["Parkinson", 587], ["'s", 596], ["disease", 599], [".", 606], ["Here", 608], ["we", 613], ["investigated", 616], ["whether", 629], ["mitochondrial", 637], ["motility", 651], [",", 659], ["dynamics", 661], ["and", 670], ["respiratory", 674], ["function", 686], ["are", 695], ["affected", 699], ["in", 708], ["primary", 711], ["neurons", 719], ["from", 727], ["a", 732], ["mouse", 734], ["model", 740], ["expressing", 746], ["the", 757], ["human", 761], ["A53", 767], ["T", 770], ["mutation", 772], [".", 780], ["We", 782], ["found", 785], ["that", 791], ["mitochondrial", 796], ["motility", 810], ["was", 819], ["selectively", 823], ["inhibited", 835], ["in", 845], ["A53", 848], ["T", 851], ["neurons", 853], ["while", 861], ["transport", 867], ["of", 877], ["other", 880], ["organelles", 886], ["was", 897], ["not", 901], ["affected", 905], [".", 913], ["In", 915], ["addition", 918], [",", 926], ["A53", 928], ["T", 931], ["expressing", 933], ["neurons", 944], ["showed", 952], ["impairment", 959], ["in", 970], ["mitochondrial", 973], ["membrane", 987], ["potential", 996], ["and", 1006], ["mitochondrial", 1010], ["respiratory", 1024], ["function", 1036], [".", 1044], ["Furthermore", 1046], [",", 1057], ["we", 1059], ["found", 1062], ["that", 1068], ["rapamycin", 1073], [",", 1082], ["an", 1084], ["autophagy", 1087], ["inducer", 1097], [",", 1104], ["rescued", 1106], ["the", 1114], ["decreased", 1118], ["mitochondrial", 1128], ["mobility", 1142], [".", 1150], ["Taken", 1152], ["together", 1158], [",", 1166], ["these", 1168], ["data", 1174], ["demonstrate", 1179], ["that", 1191], ["A53", 1196], ["T", 1199], ["\u03b1", 1201], ["-", 1202], ["syn", 1203], ["impairs", 1207], ["mitochondrial", 1215], ["function", 1229], ["and", 1238], ["dynamics", 1242], ["and", 1251], ["the", 1255], ["deficit", 1259], ["of", 1267], ["mitochondrial", 1270], ["transport", 1284], ["is", 1294], ["reversible", 1297], [",", 1307], ["providing", 1309], ["further", 1319], ["understanding", 1327], ["of", 1341], ["the", 1344], ["disease", 1348], ["pathogenesis", 1356], ["and", 1369], ["a", 1373], ["potential", 1375], ["therapeutic", 1385], ["strategy", 1397], ["for", 1406], ["PD", 1410], [".", 1412]]}
{"context": "Loss-of-function mutations in the gene ced-8 lead to the late appearance of cell corpses during embryonic development in C. elegans. ced-8 functions downstream of or in parallel to-the regulatory cell death gene ced-9 and may function as a cell death effector downstream of the caspase encoded by the programmed cell death killer gene ced-3. In ced-8 mutants, embryonic programmed cell death probably initiates normally but proceeds slowly. ced-8 encodes a transmembrane protein that appears to be localized to the plasma membrane. The CED-8 protein is similar to human XK, a putative membrane transport protein implicated in McLeod Syndrome, a form of hereditary neuroacanthocytosis.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "0574b68d8a1845829336d0bb8c46aef6", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[99, 99]], "char_spans": [[570, 571]]}]}], "context_tokens": [["Loss", 0], ["-", 4], ["of", 5], ["-", 7], ["function", 8], ["mutations", 17], ["in", 27], ["the", 30], ["gene", 34], ["ced-8", 39], ["lead", 45], ["to", 50], ["the", 53], ["late", 57], ["appearance", 62], ["of", 73], ["cell", 76], ["corpses", 81], ["during", 89], ["embryonic", 96], ["development", 106], ["in", 118], ["C.", 121], ["elegans", 124], [".", 131], ["ced-8", 133], ["functions", 139], ["downstream", 149], ["of", 160], ["or", 163], ["in", 166], ["parallel", 169], ["to", 178], ["-", 180], ["the", 181], ["regulatory", 185], ["cell", 196], ["death", 201], ["gene", 207], ["ced-9", 212], ["and", 218], ["may", 222], ["function", 226], ["as", 235], ["a", 238], ["cell", 240], ["death", 245], ["effector", 251], ["downstream", 260], ["of", 271], ["the", 274], ["caspase", 278], ["encoded", 286], ["by", 294], ["the", 297], ["programmed", 301], ["cell", 312], ["death", 317], ["killer", 323], ["gene", 330], ["ced-3", 335], [".", 340], ["In", 342], ["ced-8", 345], ["mutants", 351], [",", 358], ["embryonic", 360], ["programmed", 370], ["cell", 381], ["death", 386], ["probably", 392], ["initiates", 401], ["normally", 411], ["but", 420], ["proceeds", 424], ["slowly", 433], [".", 439], ["ced-8", 441], ["encodes", 447], ["a", 455], ["transmembrane", 457], ["protein", 471], ["that", 479], ["appears", 484], ["to", 492], ["be", 495], ["localized", 498], ["to", 508], ["the", 511], ["plasma", 515], ["membrane", 522], [".", 530], ["The", 532], ["CED-8", 536], ["protein", 542], ["is", 550], ["similar", 553], ["to", 561], ["human", 564], ["XK", 570], [",", 572], ["a", 574], ["putative", 576], ["membrane", 585], ["transport", 594], ["protein", 604], ["implicated", 612], ["in", 623], ["McLeod", 626], ["Syndrome", 633], [",", 641], ["a", 643], ["form", 645], ["of", 650], ["hereditary", 653], ["neuroacanthocytosis", 664], [".", 683]]}
{"context": "Alpha-synuclein forms the major component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies. Here we show that alpha-synuclein is also the major component of the filamentous inclusions of multiple system atrophy which comprises several neurodegenerative diseases with a shared filamentous pathology in nerve cells and glial cells. These findings provide an unexpected link between multiple system atrophy and Lewy body disorders and establish that alpha-synucleinopathies constitute a major class of human neurodegenerative disorder.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a4da3f3b9ad440b69aaf79b7d6f6f893", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2], [32, 34]], "char_spans": [[0, 14], [195, 209]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["forms", 16], ["the", 22], ["major", 26], ["component", 32], ["of", 42], ["Lewy", 45], ["bodies", 50], ["and", 57], ["Lewy", 61], ["neurites", 66], [",", 74], ["the", 76], ["defining", 80], ["neuropathological", 89], ["characteristics", 107], ["of", 123], ["Parkinson", 126], ["'s", 135], ["disease", 138], ["and", 146], ["dementia", 150], ["with", 159], ["Lewy", 164], ["bodies", 169], [".", 175], ["Here", 177], ["we", 182], ["show", 185], ["that", 190], ["alpha", 195], ["-", 200], ["synuclein", 201], ["is", 211], ["also", 214], ["the", 219], ["major", 223], ["component", 229], ["of", 239], ["the", 242], ["filamentous", 246], ["inclusions", 258], ["of", 269], ["multiple", 272], ["system", 281], ["atrophy", 288], ["which", 296], ["comprises", 302], ["several", 312], ["neurodegenerative", 320], ["diseases", 338], ["with", 347], ["a", 352], ["shared", 354], ["filamentous", 361], ["pathology", 373], ["in", 383], ["nerve", 386], ["cells", 392], ["and", 398], ["glial", 402], ["cells", 408], [".", 413], ["These", 415], ["findings", 421], ["provide", 430], ["an", 438], ["unexpected", 441], ["link", 452], ["between", 457], ["multiple", 465], ["system", 474], ["atrophy", 481], ["and", 489], ["Lewy", 493], ["body", 498], ["disorders", 503], ["and", 513], ["establish", 517], ["that", 527], ["alpha", 532], ["-", 537], ["synucleinopathies", 538], ["constitute", 556], ["a", 567], ["major", 569], ["class", 575], ["of", 581], ["human", 584], ["neurodegenerative", 590], ["disorder", 608], [".", 616]]}
{"context": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500). An unusally elevated level of plasma alpha-Gal A activity (> 2.5 times the normal mean) was detected in two unrelated normal males and the elevated activities were inherited as X-linked traits in their families. Sequencing of the alpha-Gal A coding region, intron/exon boundaries and 5'-flanking region from the proband identified a single mutation, a G-->A transition 30 nt upstream from the initiation of translation codon in exon 1. The -30G-->A mutation occurred in a putative NF kappa B/Ets consensus binding site that was recently shown to inhibit protein binding to the 5'-untranslated region of the gene, providing a possible explanation for its high activity. To further characterize the mutation, the mRNA and protein expressed by this variant allele were studied. Purified plasma and lymphoblast alpha-Gal A activity from individuals with the -30G-->A mutation had normal physical and kinetic properties. In vitro translation of mRNAs from the cloned normal and high plasma activity alleles resulted in similar levels of alpha-Gal A protein, indicating that this mutation did not enhance translation. These findings suggest that the -30G-->A mutation in the 5'-untranslated region of the alpha-Gal A gene enhances transcription, presumably by interfering with the binding of negatively-acting transcription factors which normally decrease alpha-Gal A expression in various cells. Preliminary studies of the frequency of the -30G-->A mutation in 395 unrelated normal males of mixed ancestry revealed two additional unrelated individuals who had high plasma enzymatic activity and the mutation, confirming the effect of this mutation on enzyme expression and suggesting that about 0.5% of normal individuals have high plasma alpha-Gal A activity due to this variant allele.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "cd3dcbcaf34943d0be36358f319a997a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[1, 3]], "char_spans": [[6, 24]]}]}], "context_tokens": [["Human", 0], ["alpha", 6], ["-", 11], ["galactosidase", 12], ["A", 26], ["(", 28], ["EC", 29], ["3.2.1.22", 32], [";", 40], ["alpha", 42], ["-", 47], ["Gal", 48], ["A", 52], [")", 53], ["is", 55], ["the", 58], ["lysosomal", 62], ["exoglycosidase", 72], ["responsible", 87], ["for", 99], ["the", 103], ["hydrolysis", 107], ["of", 118], ["terminal", 121], ["alpha", 130], ["-", 135], ["galactosyl", 136], ["residues", 147], ["from", 156], ["glycoconjugates", 161], ["and", 177], ["is", 181], ["the", 184], ["defective", 188], ["enzyme", 198], ["causing", 205], ["Fabry", 213], ["disease", 219], ["(", 227], ["McKusick", 228], ["301500", 237], [")", 243], [".", 244], ["An", 246], ["unusally", 249], ["elevated", 258], ["level", 267], ["of", 273], ["plasma", 276], ["alpha", 283], ["-", 288], ["Gal", 289], ["A", 293], ["activity", 295], ["(", 304], [">", 305], ["2.5", 307], ["times", 311], ["the", 317], ["normal", 321], ["mean", 328], [")", 332], ["was", 334], ["detected", 338], ["in", 347], ["two", 350], ["unrelated", 354], ["normal", 364], ["males", 371], ["and", 377], ["the", 381], ["elevated", 385], ["activities", 394], ["were", 405], ["inherited", 410], ["as", 420], ["X", 423], ["-", 424], ["linked", 425], ["traits", 432], ["in", 439], ["their", 442], ["families", 448], [".", 456], ["Sequencing", 458], ["of", 469], ["the", 472], ["alpha", 476], ["-", 481], ["Gal", 482], ["A", 486], ["coding", 488], ["region", 495], [",", 501], ["intron", 503], ["/", 509], ["exon", 510], ["boundaries", 515], ["and", 526], ["5'-flanking", 530], ["region", 542], ["from", 549], ["the", 554], ["proband", 558], ["identified", 566], ["a", 577], ["single", 579], ["mutation", 586], [",", 594], ["a", 596], ["G-->A", 598], ["transition", 604], ["30", 615], ["nt", 618], ["upstream", 621], ["from", 630], ["the", 635], ["initiation", 639], ["of", 650], ["translation", 653], ["codon", 665], ["in", 671], ["exon", 674], ["1", 679], [".", 680], ["The", 682], ["-30G-->A", 686], ["mutation", 695], ["occurred", 704], ["in", 713], ["a", 716], ["putative", 718], ["NF", 727], ["kappa", 730], ["B", 736], ["/", 737], ["Ets", 738], ["consensus", 742], ["binding", 752], ["site", 760], ["that", 765], ["was", 770], ["recently", 774], ["shown", 783], ["to", 789], ["inhibit", 792], ["protein", 800], ["binding", 808], ["to", 816], ["the", 819], ["5'-untranslated", 823], ["region", 839], ["of", 846], ["the", 849], ["gene", 853], [",", 857], ["providing", 859], ["a", 869], ["possible", 871], ["explanation", 880], ["for", 892], ["its", 896], ["high", 900], ["activity", 905], [".", 913], ["To", 915], ["further", 918], ["characterize", 926], ["the", 939], ["mutation", 943], [",", 951], ["the", 953], ["mRNA", 957], ["and", 962], ["protein", 966], ["expressed", 974], ["by", 984], ["this", 987], ["variant", 992], ["allele", 1000], ["were", 1007], ["studied", 1012], [".", 1019], ["Purified", 1021], ["plasma", 1030], ["and", 1037], ["lymphoblast", 1041], ["alpha", 1053], ["-", 1058], ["Gal", 1059], ["A", 1063], ["activity", 1065], ["from", 1074], ["individuals", 1079], ["with", 1091], ["the", 1096], ["-30G-->A", 1100], ["mutation", 1109], ["had", 1118], ["normal", 1122], ["physical", 1129], ["and", 1138], ["kinetic", 1142], ["properties", 1150], [".", 1160], ["In", 1162], ["vitro", 1165], ["translation", 1171], ["of", 1183], ["mRNAs", 1186], ["from", 1192], ["the", 1197], ["cloned", 1201], ["normal", 1208], ["and", 1215], ["high", 1219], ["plasma", 1224], ["activity", 1231], ["alleles", 1240], ["resulted", 1248], ["in", 1257], ["similar", 1260], ["levels", 1268], ["of", 1275], ["alpha", 1278], ["-", 1283], ["Gal", 1284], ["A", 1288], ["protein", 1290], [",", 1297], ["indicating", 1299], ["that", 1310], ["this", 1315], ["mutation", 1320], ["did", 1329], ["not", 1333], ["enhance", 1337], ["translation", 1345], [".", 1356], ["These", 1358], ["findings", 1364], ["suggest", 1373], ["that", 1381], ["the", 1386], ["-30G-->A", 1390], ["mutation", 1399], ["in", 1408], ["the", 1411], ["5'-untranslated", 1415], ["region", 1431], ["of", 1438], ["the", 1441], ["alpha", 1445], ["-", 1450], ["Gal", 1451], ["A", 1455], ["gene", 1457], ["enhances", 1462], ["transcription", 1471], [",", 1484], ["presumably", 1486], ["by", 1497], ["interfering", 1500], ["with", 1512], ["the", 1517], ["binding", 1521], ["of", 1529], ["negatively", 1532], ["-", 1542], ["acting", 1543], ["transcription", 1550], ["factors", 1564], ["which", 1572], ["normally", 1578], ["decrease", 1587], ["alpha", 1596], ["-", 1601], ["Gal", 1602], ["A", 1606], ["expression", 1608], ["in", 1619], ["various", 1622], ["cells", 1630], [".", 1635], ["Preliminary", 1637], ["studies", 1649], ["of", 1657], ["the", 1660], ["frequency", 1664], ["of", 1674], ["the", 1677], ["-30G-->A", 1681], ["mutation", 1690], ["in", 1699], ["395", 1702], ["unrelated", 1706], ["normal", 1716], ["males", 1723], ["of", 1729], ["mixed", 1732], ["ancestry", 1738], ["revealed", 1747], ["two", 1756], ["additional", 1760], ["unrelated", 1771], ["individuals", 1781], ["who", 1793], ["had", 1797], ["high", 1801], ["plasma", 1806], ["enzymatic", 1813], ["activity", 1823], ["and", 1832], ["the", 1836], ["mutation", 1840], [",", 1848], ["confirming", 1850], ["the", 1861], ["effect", 1865], ["of", 1872], ["this", 1875], ["mutation", 1880], ["on", 1889], ["enzyme", 1892], ["expression", 1899], ["and", 1910], ["suggesting", 1914], ["that", 1925], ["about", 1930], ["0.5", 1936], ["%", 1939], ["of", 1941], ["normal", 1944], ["individuals", 1951], ["have", 1963], ["high", 1968], ["plasma", 1973], ["alpha", 1980], ["-", 1985], ["Gal", 1986], ["A", 1990], ["activity", 1992], ["due", 2001], ["to", 2005], ["this", 2008], ["variant", 2013], ["allele", 2021], [".", 2027]]}
{"context": "The clinical efficacy of different doses of the specific benzodiazepine antagonist flumazenil was studied in a total of 72 patients with benzodiazepine or ethanol overdose. In a randomized double-blind study, 18 patients (group 1) and eight patients (group 2) with suspected benzodiazepine overdose received 5 mg (group 1) or 1 mg (group 2) flumazenil or placebo, respectively. The stage of coma, heart rate, blood pressure and respiratory rate were monitored within the following 15 min. If no change in the stage of coma was observed, 5 mg (group 1) or 1 mg (group 2) flumazenil were given, and the stage of coma, heart rate and blood pressure were again monitored. In a similar way, the effect of 5 and 1 mg flumazenil was investigated in 13 patients (group 3) and four patients (group 4) with ethanol intoxication. In an open trial, the clinical efficacy of flumazenil for the diagnosis of benzodiazepine or ethanol overdose was studied in 29 patients (group 5). In all patients, a toxicological screening confirmed benzodiazepine or ethanol overdose. None of the patients receiving placebo showed effects on stage of coma, heart rate, blood pressure or respiratory rate. Patients with benzodiazepine overdose who received 5 mg flumazenil regained consciousness about 1-2 min after the end of injection. The effect of 1 mg flumazenil (group 2) on benzodiazepine-induced coma was less pronounced. In patients with ethanol overdose (group 3), ethanol-induced coma was reversed after 5 mg flumazenil more slowly than in patients of group 1. No effect of flumazenil on ethanol-induced coma was observed in group 4. In group 5, flumazenil proved to be useful for diagnosing benzodiazepine or ethanol intoxication. In one patient with coma due to carbamazepine overdose, flumazenil was also found to be effective. Additionally, a possible analytical interference of flumazenil and its metabolites with the identification of other benzodiazepines by a toxicological screening procedure was studied. Even after an oral dose of 200 mg flumazenil, no interference with immunological benzodiazepine assays (EMIT, TDX, and RIA) was found. A metabolite and an artifact of flumazenil could be identified in urine by gas chromatography/mass spectrometry.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "09099c4d930143fdb85f846a03675594", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[304, 304], [320, 320], [147, 147], [11, 11], [177, 177], [291, 291], [342, 342], [357, 357], [116, 116], [383, 383], [408, 408], [258, 258], [239, 239], [65, 65]], "char_spans": [[1555, 1564], [1627, 1636], [711, 720], [83, 92], [862, 871], [1490, 1499], [1769, 1778], [1864, 1873], [570, 579], [2030, 2039], [2163, 2172], [1327, 1336], [1232, 1241], [341, 350]]}]}], "context_tokens": [["The", 0], ["clinical", 4], ["efficacy", 13], ["of", 22], ["different", 25], ["doses", 35], ["of", 41], ["the", 44], ["specific", 48], ["benzodiazepine", 57], ["antagonist", 72], ["flumazenil", 83], ["was", 94], ["studied", 98], ["in", 106], ["a", 109], ["total", 111], ["of", 117], ["72", 120], ["patients", 123], ["with", 132], ["benzodiazepine", 137], ["or", 152], ["ethanol", 155], ["overdose", 163], [".", 171], ["In", 173], ["a", 176], ["randomized", 178], ["double", 189], ["-", 195], ["blind", 196], ["study", 202], [",", 207], ["18", 209], ["patients", 212], ["(", 221], ["group", 222], ["1", 228], [")", 229], ["and", 231], ["eight", 235], ["patients", 241], ["(", 250], ["group", 251], ["2", 257], [")", 258], ["with", 260], ["suspected", 265], ["benzodiazepine", 275], ["overdose", 290], ["received", 299], ["5", 308], ["mg", 310], ["(", 313], ["group", 314], ["1", 320], [")", 321], ["or", 323], ["1", 326], ["mg", 328], ["(", 331], ["group", 332], ["2", 338], [")", 339], ["flumazenil", 341], ["or", 352], ["placebo", 355], [",", 362], ["respectively", 364], [".", 376], ["The", 378], ["stage", 382], ["of", 388], ["coma", 391], [",", 395], ["heart", 397], ["rate", 403], [",", 407], ["blood", 409], ["pressure", 415], ["and", 424], ["respiratory", 428], ["rate", 440], ["were", 445], ["monitored", 450], ["within", 460], ["the", 467], ["following", 471], ["15", 481], ["min", 484], [".", 487], ["If", 489], ["no", 492], ["change", 495], ["in", 502], ["the", 505], ["stage", 509], ["of", 515], ["coma", 518], ["was", 523], ["observed", 527], [",", 535], ["5", 537], ["mg", 539], ["(", 542], ["group", 543], ["1", 549], [")", 550], ["or", 552], ["1", 555], ["mg", 557], ["(", 560], ["group", 561], ["2", 567], [")", 568], ["flumazenil", 570], ["were", 581], ["given", 586], [",", 591], ["and", 593], ["the", 597], ["stage", 601], ["of", 607], ["coma", 610], [",", 614], ["heart", 616], ["rate", 622], ["and", 627], ["blood", 631], ["pressure", 637], ["were", 646], ["again", 651], ["monitored", 657], [".", 666], ["In", 668], ["a", 671], ["similar", 673], ["way", 681], [",", 684], ["the", 686], ["effect", 690], ["of", 697], ["5", 700], ["and", 702], ["1", 706], ["mg", 708], ["flumazenil", 711], ["was", 722], ["investigated", 726], ["in", 739], ["13", 742], ["patients", 745], ["(", 754], ["group", 755], ["3", 761], [")", 762], ["and", 764], ["four", 768], ["patients", 773], ["(", 782], ["group", 783], ["4", 789], [")", 790], ["with", 792], ["ethanol", 797], ["intoxication", 805], [".", 817], ["In", 819], ["an", 822], ["open", 825], ["trial", 830], [",", 835], ["the", 837], ["clinical", 841], ["efficacy", 850], ["of", 859], ["flumazenil", 862], ["for", 873], ["the", 877], ["diagnosis", 881], ["of", 891], ["benzodiazepine", 894], ["or", 909], ["ethanol", 912], ["overdose", 920], ["was", 929], ["studied", 933], ["in", 941], ["29", 944], ["patients", 947], ["(", 956], ["group", 957], ["5", 963], [")", 964], [".", 965], ["In", 967], ["all", 970], ["patients", 974], [",", 982], ["a", 984], ["toxicological", 986], ["screening", 1000], ["confirmed", 1010], ["benzodiazepine", 1020], ["or", 1035], ["ethanol", 1038], ["overdose", 1046], [".", 1054], ["None", 1056], ["of", 1061], ["the", 1064], ["patients", 1068], ["receiving", 1077], ["placebo", 1087], ["showed", 1095], ["effects", 1102], ["on", 1110], ["stage", 1113], ["of", 1119], ["coma", 1122], [",", 1126], ["heart", 1128], ["rate", 1134], [",", 1138], ["blood", 1140], ["pressure", 1146], ["or", 1155], ["respiratory", 1158], ["rate", 1170], [".", 1174], ["Patients", 1176], ["with", 1185], ["benzodiazepine", 1190], ["overdose", 1205], ["who", 1214], ["received", 1218], ["5", 1227], ["mg", 1229], ["flumazenil", 1232], ["regained", 1243], ["consciousness", 1252], ["about", 1266], ["1", 1272], ["-", 1273], ["2", 1274], ["min", 1276], ["after", 1280], ["the", 1286], ["end", 1290], ["of", 1294], ["injection", 1297], [".", 1306], ["The", 1308], ["effect", 1312], ["of", 1319], ["1", 1322], ["mg", 1324], ["flumazenil", 1327], ["(", 1338], ["group", 1339], ["2", 1345], [")", 1346], ["on", 1348], ["benzodiazepine", 1351], ["-", 1365], ["induced", 1366], ["coma", 1374], ["was", 1379], ["less", 1383], ["pronounced", 1388], [".", 1398], ["In", 1400], ["patients", 1403], ["with", 1412], ["ethanol", 1417], ["overdose", 1425], ["(", 1434], ["group", 1435], ["3", 1441], [")", 1442], [",", 1443], ["ethanol", 1445], ["-", 1452], ["induced", 1453], ["coma", 1461], ["was", 1466], ["reversed", 1470], ["after", 1479], ["5", 1485], ["mg", 1487], ["flumazenil", 1490], ["more", 1501], ["slowly", 1506], ["than", 1513], ["in", 1518], ["patients", 1521], ["of", 1530], ["group", 1533], ["1", 1539], [".", 1540], ["No", 1542], ["effect", 1545], ["of", 1552], ["flumazenil", 1555], ["on", 1566], ["ethanol", 1569], ["-", 1576], ["induced", 1577], ["coma", 1585], ["was", 1590], ["observed", 1594], ["in", 1603], ["group", 1606], ["4", 1612], [".", 1613], ["In", 1615], ["group", 1618], ["5", 1624], [",", 1625], ["flumazenil", 1627], ["proved", 1638], ["to", 1645], ["be", 1648], ["useful", 1651], ["for", 1658], ["diagnosing", 1662], ["benzodiazepine", 1673], ["or", 1688], ["ethanol", 1691], ["intoxication", 1699], [".", 1711], ["In", 1713], ["one", 1716], ["patient", 1720], ["with", 1728], ["coma", 1733], ["due", 1738], ["to", 1742], ["carbamazepine", 1745], ["overdose", 1759], [",", 1767], ["flumazenil", 1769], ["was", 1780], ["also", 1784], ["found", 1789], ["to", 1795], ["be", 1798], ["effective", 1801], [".", 1810], ["Additionally", 1812], [",", 1824], ["a", 1826], ["possible", 1828], ["analytical", 1837], ["interference", 1848], ["of", 1861], ["flumazenil", 1864], ["and", 1875], ["its", 1879], ["metabolites", 1883], ["with", 1895], ["the", 1900], ["identification", 1904], ["of", 1919], ["other", 1922], ["benzodiazepines", 1928], ["by", 1944], ["a", 1947], ["toxicological", 1949], ["screening", 1963], ["procedure", 1973], ["was", 1983], ["studied", 1987], [".", 1994], ["Even", 1996], ["after", 2001], ["an", 2007], ["oral", 2010], ["dose", 2015], ["of", 2020], ["200", 2023], ["mg", 2027], ["flumazenil", 2030], [",", 2040], ["no", 2042], ["interference", 2045], ["with", 2058], ["immunological", 2063], ["benzodiazepine", 2077], ["assays", 2092], ["(", 2099], ["EMIT", 2100], [",", 2104], ["TDX", 2106], [",", 2109], ["and", 2111], ["RIA", 2115], [")", 2118], ["was", 2120], ["found", 2124], [".", 2129], ["A", 2131], ["metabolite", 2133], ["and", 2144], ["an", 2148], ["artifact", 2151], ["of", 2160], ["flumazenil", 2163], ["could", 2174], ["be", 2180], ["identified", 2183], ["in", 2194], ["urine", 2197], ["by", 2203], ["gas", 2206], ["chromatography", 2210], ["/", 2224], ["mass", 2225], ["spectrometry", 2230], [".", 2242]]}
{"context": "Parkinson's disease (PD) is a neurodegenerative disease with characteristics and symptoms that are well defined. Nevertheless, its aetiology remains unknown. PD is characterized by the presence of Lewy bodies inside neurons. \u03b1-Synuclein (\u03b1-syn) is a soluble protein present in the pre-synaptic terminal of neurons. Evidence suggests that \u03b1-syn has a fundamental role in PD pathogenesis, given that it is an important component of Lewy bodies localized in the dopaminergic neurons of PD patients. In the present study, we investigated the influence of wild type (WT) and A30P \u03b1-syn overexpression on neuroblastoma SH-SY5Y toxicity induced by the conditioned medium (CM) from primary cultures of glia challenged with lipopolysaccharide (LPS) from Escherichia coli. We observed that SH-SY5Y cells transduced with \u03b1-syn (WT or A30P) and treated with CM from LPS-activated glia cells show evidence of cell death, which is not reverted by NF-\u03baB inhibition by sodium salicylate or by blockage of P50 (NF-\u03baB subunit). Furthermore, the expression of A30P \u03b1-syn in neuroblastoma SH-SY5Y decreases the cell death triggered by the CM of activated glia versus WT \u03b1-syn or control group. This effect of A30P \u03b1-syn may be due to the low MAPK42/44 phosphorylation. This finding is substantiated by MEK1 inhibition by PD98059, decreasing LDH release by CM in SH-SY5Y cells. Our results suggest that SH-SY5Y cells transduced with \u03b1-syn (WT or A30P) and treated with CM from LPS-activated glia cells show cell death, which is not reverted by NF-\u03baB blockage. Additionally, the expression of A30P \u03b1-syn on neuroblastoma SH-SY5Y leads to decreased cell death triggered by the CM of activated glia, when compared to WT \u03b1-syn or control group. The mechanism underlying this process remains to be completely elucidated, but the present data suggest that MAPK42/44 phosphorylation plays an important role in this process. CRD42015020829.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "770cdf4bff11453d9e85c2d6c5857367", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[38, 40]], "char_spans": [[225, 235]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegenerative", 30], ["disease", 48], ["with", 56], ["characteristics", 61], ["and", 77], ["symptoms", 81], ["that", 90], ["are", 95], ["well", 99], ["defined", 104], [".", 111], ["Nevertheless", 113], [",", 125], ["its", 127], ["aetiology", 131], ["remains", 141], ["unknown", 149], [".", 156], ["PD", 158], ["is", 161], ["characterized", 164], ["by", 178], ["the", 181], ["presence", 185], ["of", 194], ["Lewy", 197], ["bodies", 202], ["inside", 209], ["neurons", 216], [".", 223], ["\u03b1", 225], ["-", 226], ["Synuclein", 227], ["(", 237], ["\u03b1", 238], ["-", 239], ["syn", 240], [")", 243], ["is", 245], ["a", 248], ["soluble", 250], ["protein", 258], ["present", 266], ["in", 274], ["the", 277], ["pre", 281], ["-", 284], ["synaptic", 285], ["terminal", 294], ["of", 303], ["neurons", 306], [".", 313], ["Evidence", 315], ["suggests", 324], ["that", 333], ["\u03b1", 338], ["-", 339], ["syn", 340], ["has", 344], ["a", 348], ["fundamental", 350], ["role", 362], ["in", 367], ["PD", 370], ["pathogenesis", 373], [",", 385], ["given", 387], ["that", 393], ["it", 398], ["is", 401], ["an", 404], ["important", 407], ["component", 417], ["of", 427], ["Lewy", 430], ["bodies", 435], ["localized", 442], ["in", 452], ["the", 455], ["dopaminergic", 459], ["neurons", 472], ["of", 480], ["PD", 483], ["patients", 486], [".", 494], ["In", 496], ["the", 499], ["present", 503], ["study", 511], [",", 516], ["we", 518], ["investigated", 521], ["the", 534], ["influence", 538], ["of", 548], ["wild", 551], ["type", 556], ["(", 561], ["WT", 562], [")", 564], ["and", 566], ["A30P", 570], ["\u03b1", 575], ["-", 576], ["syn", 577], ["overexpression", 581], ["on", 596], ["neuroblastoma", 599], ["SH", 613], ["-", 615], ["SY5Y", 616], ["toxicity", 621], ["induced", 630], ["by", 638], ["the", 641], ["conditioned", 645], ["medium", 657], ["(", 664], ["CM", 665], [")", 667], ["from", 669], ["primary", 674], ["cultures", 682], ["of", 691], ["glia", 694], ["challenged", 699], ["with", 710], ["lipopolysaccharide", 715], ["(", 734], ["LPS", 735], [")", 738], ["from", 740], ["Escherichia", 745], ["coli", 757], [".", 761], ["We", 763], ["observed", 766], ["that", 775], ["SH", 780], ["-", 782], ["SY5Y", 783], ["cells", 788], ["transduced", 794], ["with", 805], ["\u03b1", 810], ["-", 811], ["syn", 812], ["(", 816], ["WT", 817], ["or", 820], ["A30P", 823], [")", 827], ["and", 829], ["treated", 833], ["with", 841], ["CM", 846], ["from", 849], ["LPS", 854], ["-", 857], ["activated", 858], ["glia", 868], ["cells", 873], ["show", 879], ["evidence", 884], ["of", 893], ["cell", 896], ["death", 901], [",", 906], ["which", 908], ["is", 914], ["not", 917], ["reverted", 921], ["by", 930], ["NF", 933], ["-", 935], ["\u03baB", 936], ["inhibition", 939], ["by", 950], ["sodium", 953], ["salicylate", 960], ["or", 971], ["by", 974], ["blockage", 977], ["of", 986], ["P50", 989], ["(", 993], ["NF", 994], ["-", 996], ["\u03baB", 997], ["subunit", 1000], [")", 1007], [".", 1008], ["Furthermore", 1010], [",", 1021], ["the", 1023], ["expression", 1027], ["of", 1038], ["A30P", 1041], ["\u03b1", 1046], ["-", 1047], ["syn", 1048], ["in", 1052], ["neuroblastoma", 1055], ["SH", 1069], ["-", 1071], ["SY5Y", 1072], ["decreases", 1077], ["the", 1087], ["cell", 1091], ["death", 1096], ["triggered", 1102], ["by", 1112], ["the", 1115], ["CM", 1119], ["of", 1122], ["activated", 1125], ["glia", 1135], ["versus", 1140], ["WT", 1147], ["\u03b1", 1150], ["-", 1151], ["syn", 1152], ["or", 1156], ["control", 1159], ["group", 1167], [".", 1172], ["This", 1174], ["effect", 1179], ["of", 1186], ["A30P", 1189], ["\u03b1", 1194], ["-", 1195], ["syn", 1196], ["may", 1200], ["be", 1204], ["due", 1207], ["to", 1211], ["the", 1214], ["low", 1218], ["MAPK42/44", 1222], ["phosphorylation", 1232], [".", 1247], ["This", 1249], ["finding", 1254], ["is", 1262], ["substantiated", 1265], ["by", 1279], ["MEK1", 1282], ["inhibition", 1287], ["by", 1298], ["PD98059", 1301], [",", 1308], ["decreasing", 1310], ["LDH", 1321], ["release", 1325], ["by", 1333], ["CM", 1336], ["in", 1339], ["SH", 1342], ["-", 1344], ["SY5Y", 1345], ["cells", 1350], [".", 1355], ["Our", 1357], ["results", 1361], ["suggest", 1369], ["that", 1377], ["SH", 1382], ["-", 1384], ["SY5Y", 1385], ["cells", 1390], ["transduced", 1396], ["with", 1407], ["\u03b1", 1412], ["-", 1413], ["syn", 1414], ["(", 1418], ["WT", 1419], ["or", 1422], ["A30P", 1425], [")", 1429], ["and", 1431], ["treated", 1435], ["with", 1443], ["CM", 1448], ["from", 1451], ["LPS", 1456], ["-", 1459], ["activated", 1460], ["glia", 1470], ["cells", 1475], ["show", 1481], ["cell", 1486], ["death", 1491], [",", 1496], ["which", 1498], ["is", 1504], ["not", 1507], ["reverted", 1511], ["by", 1520], ["NF", 1523], ["-", 1525], ["\u03baB", 1526], ["blockage", 1529], [".", 1537], ["Additionally", 1539], [",", 1551], ["the", 1553], ["expression", 1557], ["of", 1568], ["A30P", 1571], ["\u03b1", 1576], ["-", 1577], ["syn", 1578], ["on", 1582], ["neuroblastoma", 1585], ["SH", 1599], ["-", 1601], ["SY5Y", 1602], ["leads", 1607], ["to", 1613], ["decreased", 1616], ["cell", 1626], ["death", 1631], ["triggered", 1637], ["by", 1647], ["the", 1650], ["CM", 1654], ["of", 1657], ["activated", 1660], ["glia", 1670], [",", 1674], ["when", 1676], ["compared", 1681], ["to", 1690], ["WT", 1693], ["\u03b1", 1696], ["-", 1697], ["syn", 1698], ["or", 1702], ["control", 1705], ["group", 1713], [".", 1718], ["The", 1720], ["mechanism", 1724], ["underlying", 1734], ["this", 1745], ["process", 1750], ["remains", 1758], ["to", 1766], ["be", 1769], ["completely", 1772], ["elucidated", 1783], [",", 1793], ["but", 1795], ["the", 1799], ["present", 1803], ["data", 1811], ["suggest", 1816], ["that", 1824], ["MAPK42/44", 1829], ["phosphorylation", 1839], ["plays", 1855], ["an", 1861], ["important", 1864], ["role", 1874], ["in", 1879], ["this", 1882], ["process", 1887], [".", 1894], ["CRD42015020829", 1896], [".", 1910]]}
{"context": "Although peak finding in next-generation sequencing (NGS) datasets has been addressed extensively, there is no consensus on how to analyze and process biological replicates. Furthermore, most peak finders do not focus on accurate determination of enrichment site widths and are not widely applicable to different types of datasets. We developed JAMM (Joint Analysis of NGS replicates via Mixture Model clustering): a peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM is a universal peak finder that is applicable to different types of datasets. We show that JAMM is among the best performing peak finders in terms of site detection accuracy and in terms of accurate determination of enrichment sites widths. In addition, JAMM's replicate integration improves peak spatial resolution, sorting and peak finding accuracy. JAMM is available for free and can run on Linux machines through the command line: http://code.google.com/p/jamm-peak-finder.", "qas": [{"question": "Which peak calling algorithm employs mixture model clustering under the hood?", "answers": ["JAMM"], "qid": "34f812a7bd0645b481c7269f56ee725d", "question_tokens": [["Which", 0], ["peak", 6], ["calling", 11], ["algorithm", 19], ["employs", 29], ["mixture", 37], ["model", 45], ["clustering", 51], ["under", 62], ["the", 68], ["hood", 72], ["?", 76]], "detected_answers": [{"text": "JAMM", "token_spans": [[139, 139], [93, 93], [154, 154], [58, 58], [111, 111]], "char_spans": [[829, 832], [570, 573], [927, 930], [345, 348], [666, 669]]}]}], "context_tokens": [["Although", 0], ["peak", 9], ["finding", 14], ["in", 22], ["next", 25], ["-", 29], ["generation", 30], ["sequencing", 41], ["(", 52], ["NGS", 53], [")", 56], ["datasets", 58], ["has", 67], ["been", 71], ["addressed", 76], ["extensively", 86], [",", 97], ["there", 99], ["is", 105], ["no", 108], ["consensus", 111], ["on", 121], ["how", 124], ["to", 128], ["analyze", 131], ["and", 139], ["process", 143], ["biological", 151], ["replicates", 162], [".", 172], ["Furthermore", 174], [",", 185], ["most", 187], ["peak", 192], ["finders", 197], ["do", 205], ["not", 208], ["focus", 212], ["on", 218], ["accurate", 221], ["determination", 230], ["of", 244], ["enrichment", 247], ["site", 258], ["widths", 263], ["and", 270], ["are", 274], ["not", 278], ["widely", 282], ["applicable", 289], ["to", 300], ["different", 303], ["types", 313], ["of", 319], ["datasets", 322], [".", 330], ["We", 332], ["developed", 335], ["JAMM", 345], ["(", 350], ["Joint", 351], ["Analysis", 357], ["of", 366], ["NGS", 369], ["replicates", 373], ["via", 384], ["Mixture", 388], ["Model", 396], ["clustering", 402], [")", 412], [":", 413], ["a", 415], ["peak", 417], ["finder", 422], ["that", 429], ["can", 434], ["integrate", 438], ["information", 448], ["from", 460], ["biological", 465], ["replicates", 476], [",", 486], ["determine", 488], ["enrichment", 498], ["site", 509], ["widths", 514], ["accurately", 521], ["and", 532], ["resolve", 536], ["neighboring", 544], ["narrow", 556], ["peaks", 563], [".", 568], ["JAMM", 570], ["is", 575], ["a", 578], ["universal", 580], ["peak", 590], ["finder", 595], ["that", 602], ["is", 607], ["applicable", 610], ["to", 621], ["different", 624], ["types", 634], ["of", 640], ["datasets", 643], [".", 651], ["We", 653], ["show", 656], ["that", 661], ["JAMM", 666], ["is", 671], ["among", 674], ["the", 680], ["best", 684], ["performing", 689], ["peak", 700], ["finders", 705], ["in", 713], ["terms", 716], ["of", 722], ["site", 725], ["detection", 730], ["accuracy", 740], ["and", 749], ["in", 753], ["terms", 756], ["of", 762], ["accurate", 765], ["determination", 774], ["of", 788], ["enrichment", 791], ["sites", 802], ["widths", 808], [".", 814], ["In", 816], ["addition", 819], [",", 827], ["JAMM", 829], ["'s", 833], ["replicate", 836], ["integration", 846], ["improves", 858], ["peak", 867], ["spatial", 872], ["resolution", 880], [",", 890], ["sorting", 892], ["and", 900], ["peak", 904], ["finding", 909], ["accuracy", 917], [".", 925], ["JAMM", 927], ["is", 932], ["available", 935], ["for", 945], ["free", 949], ["and", 954], ["can", 958], ["run", 962], ["on", 966], ["Linux", 969], ["machines", 975], ["through", 984], ["the", 992], ["command", 996], ["line", 1004], [":", 1008], ["http://code.google.com/p/jamm-peak-finder", 1010], [".", 1051]]}
{"context": "Neurological abnormalities associated with spiculated, \"acanthocytic\" red cells in blood have been described as neuroacanthocytosis. This is a heterogeneous group of conditions that can be clearly subdivided on the basis of recent genetic findings. The McLeod Syndrome, one of the core neuroacanthocytosis syndromes, is a rare X-linked disorder caused by mutations of the XK gene, an X-chromosomal gene of unknown function characterized by haemopoietic abnormalities and late-onset neurological and muscular defects. We report two Chilean brothers with the McLeod phenotype who showed important psychiatric features. The diagnosis may be elusive if the presence of acanthocytosis is not properly studied. We describe a method which allowed the diagnosis that unmasked acanthocytosis. Otherwise the condition could have remained undiagnosed as it had been for decades in this family. This syndrome must be considered when assessing a familial movement disorder, specially affecting males with relevant psychiatric features. A reliable test for acanthocytosis assessment is available.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c79bc1f8f85548358708cf9eb729f140", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[62, 62]], "char_spans": [[372, 373]]}]}], "context_tokens": [["Neurological", 0], ["abnormalities", 13], ["associated", 27], ["with", 38], ["spiculated", 43], [",", 53], ["\"", 55], ["acanthocytic", 56], ["\"", 68], ["red", 70], ["cells", 74], ["in", 80], ["blood", 83], ["have", 89], ["been", 94], ["described", 99], ["as", 109], ["neuroacanthocytosis", 112], [".", 131], ["This", 133], ["is", 138], ["a", 141], ["heterogeneous", 143], ["group", 157], ["of", 163], ["conditions", 166], ["that", 177], ["can", 182], ["be", 186], ["clearly", 189], ["subdivided", 197], ["on", 208], ["the", 211], ["basis", 215], ["of", 221], ["recent", 224], ["genetic", 231], ["findings", 239], [".", 247], ["The", 249], ["McLeod", 253], ["Syndrome", 260], [",", 268], ["one", 270], ["of", 274], ["the", 277], ["core", 281], ["neuroacanthocytosis", 286], ["syndromes", 306], [",", 315], ["is", 317], ["a", 320], ["rare", 322], ["X", 327], ["-", 328], ["linked", 329], ["disorder", 336], ["caused", 345], ["by", 352], ["mutations", 355], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["an", 381], ["X", 384], ["-", 385], ["chromosomal", 386], ["gene", 398], ["of", 403], ["unknown", 406], ["function", 414], ["characterized", 423], ["by", 437], ["haemopoietic", 440], ["abnormalities", 453], ["and", 467], ["late", 471], ["-", 475], ["onset", 476], ["neurological", 482], ["and", 495], ["muscular", 499], ["defects", 508], [".", 515], ["We", 517], ["report", 520], ["two", 527], ["Chilean", 531], ["brothers", 539], ["with", 548], ["the", 553], ["McLeod", 557], ["phenotype", 564], ["who", 574], ["showed", 578], ["important", 585], ["psychiatric", 595], ["features", 607], [".", 615], ["The", 617], ["diagnosis", 621], ["may", 631], ["be", 635], ["elusive", 638], ["if", 646], ["the", 649], ["presence", 653], ["of", 662], ["acanthocytosis", 665], ["is", 680], ["not", 683], ["properly", 687], ["studied", 696], [".", 703], ["We", 705], ["describe", 708], ["a", 717], ["method", 719], ["which", 726], ["allowed", 732], ["the", 740], ["diagnosis", 744], ["that", 754], ["unmasked", 759], ["acanthocytosis", 768], [".", 782], ["Otherwise", 784], ["the", 794], ["condition", 798], ["could", 808], ["have", 814], ["remained", 819], ["undiagnosed", 828], ["as", 840], ["it", 843], ["had", 846], ["been", 850], ["for", 855], ["decades", 859], ["in", 867], ["this", 870], ["family", 875], [".", 881], ["This", 883], ["syndrome", 888], ["must", 897], ["be", 902], ["considered", 905], ["when", 916], ["assessing", 921], ["a", 931], ["familial", 933], ["movement", 942], ["disorder", 951], [",", 959], ["specially", 961], ["affecting", 971], ["males", 981], ["with", 987], ["relevant", 992], ["psychiatric", 1001], ["features", 1013], [".", 1021], ["A", 1023], ["reliable", 1025], ["test", 1034], ["for", 1039], ["acanthocytosis", 1043], ["assessment", 1058], ["is", 1069], ["available", 1072], [".", 1081]]}
{"context": "CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions. For the processing of the resulting short read data, various tools are utilized. Some of these tools were specifically developed for CLIP-Seq data, whereas others were designed for the analysis of RNA-Seq data. To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data. This is because an experimental gold standard dataset on which methods can be accessed and compared, is still not available. To address this lack of a gold-standard dataset, we here present Cseq-Simulator, a simulator for PAR-CLIP, HITS-CLIP and iCLIP-data. This simulator can be applied to generate realistic datasets that can serve as surrogates for experimental gold standard dataset. In this work, we also show how Cseq-Simulator can be used to perform a comparison of steps of typical CLIP-Seq analysis pipelines, such as the read alignment or the peak calling. These comparisons show which tools are useful in different settings and also allow identifying pitfalls in the data analysis.", "qas": [{"question": "Which data simulator is available for CLIP-SEQ experiments?", "answers": ["Cseq-Simulator"], "qid": "eb43bbf0c4bb484dba710614100c1204", "question_tokens": [["Which", 0], ["data", 6], ["simulator", 11], ["is", 21], ["available", 24], ["for", 34], ["CLIP", 38], ["-", 42], ["SEQ", 43], ["experiments", 47], ["?", 58]], "detected_answers": [{"text": "Cseq-Simulator", "token_spans": [[132, 134], [179, 181]], "char_spans": [[648, 661], [877, 890]]}]}], "context_tokens": [["CLIP", 0], ["-", 4], ["Seq", 5], ["protocols", 9], ["such", 19], ["as", 24], ["PAR", 27], ["-", 30], ["CLIP", 31], [",", 35], ["HITS", 37], ["-", 41], ["CLIP", 42], ["or", 47], ["iCLIP", 50], ["allow", 56], ["a", 62], ["genome", 64], ["-", 70], ["wide", 71], ["analysis", 76], ["of", 85], ["protein", 88], ["-", 95], ["RNA", 96], ["interactions", 100], [".", 112], ["For", 114], ["the", 118], ["processing", 122], ["of", 133], ["the", 136], ["resulting", 140], ["short", 150], ["read", 156], ["data", 161], [",", 165], ["various", 167], ["tools", 175], ["are", 181], ["utilized", 185], [".", 193], ["Some", 195], ["of", 200], ["these", 203], ["tools", 209], ["were", 215], ["specifically", 220], ["developed", 233], ["for", 243], ["CLIP", 247], ["-", 251], ["Seq", 252], ["data", 256], [",", 260], ["whereas", 262], ["others", 270], ["were", 277], ["designed", 282], ["for", 291], ["the", 295], ["analysis", 299], ["of", 308], ["RNA", 311], ["-", 314], ["Seq", 315], ["data", 319], [".", 323], ["To", 325], ["this", 328], ["date", 333], [",", 337], ["however", 339], [",", 346], ["it", 348], ["has", 351], ["not", 355], ["been", 359], ["assessed", 364], ["which", 373], ["of", 379], ["the", 382], ["available", 386], ["tools", 396], ["are", 402], ["most", 406], ["appropriate", 411], ["for", 423], ["the", 427], ["analysis", 431], ["of", 440], ["CLIP", 443], ["-", 447], ["Seq", 448], ["data", 452], [".", 456], ["This", 458], ["is", 463], ["because", 466], ["an", 474], ["experimental", 477], ["gold", 490], ["standard", 495], ["dataset", 504], ["on", 512], ["which", 515], ["methods", 521], ["can", 529], ["be", 533], ["accessed", 536], ["and", 545], ["compared", 549], [",", 557], ["is", 559], ["still", 562], ["not", 568], ["available", 572], [".", 581], ["To", 583], ["address", 586], ["this", 594], ["lack", 599], ["of", 604], ["a", 607], ["gold", 609], ["-", 613], ["standard", 614], ["dataset", 623], [",", 630], ["we", 632], ["here", 635], ["present", 640], ["Cseq", 648], ["-", 652], ["Simulator", 653], [",", 662], ["a", 664], ["simulator", 666], ["for", 676], ["PAR", 680], ["-", 683], ["CLIP", 684], [",", 688], ["HITS", 690], ["-", 694], ["CLIP", 695], ["and", 700], ["iCLIP", 704], ["-", 709], ["data", 710], [".", 714], ["This", 716], ["simulator", 721], ["can", 731], ["be", 735], ["applied", 738], ["to", 746], ["generate", 749], ["realistic", 758], ["datasets", 768], ["that", 777], ["can", 782], ["serve", 786], ["as", 792], ["surrogates", 795], ["for", 806], ["experimental", 810], ["gold", 823], ["standard", 828], ["dataset", 837], [".", 844], ["In", 846], ["this", 849], ["work", 854], [",", 858], ["we", 860], ["also", 863], ["show", 868], ["how", 873], ["Cseq", 877], ["-", 881], ["Simulator", 882], ["can", 892], ["be", 896], ["used", 899], ["to", 904], ["perform", 907], ["a", 915], ["comparison", 917], ["of", 928], ["steps", 931], ["of", 937], ["typical", 940], ["CLIP", 948], ["-", 952], ["Seq", 953], ["analysis", 957], ["pipelines", 966], [",", 975], ["such", 977], ["as", 982], ["the", 985], ["read", 989], ["alignment", 994], ["or", 1004], ["the", 1007], ["peak", 1011], ["calling", 1016], [".", 1023], ["These", 1025], ["comparisons", 1031], ["show", 1043], ["which", 1048], ["tools", 1054], ["are", 1060], ["useful", 1064], ["in", 1071], ["different", 1074], ["settings", 1084], ["and", 1093], ["also", 1097], ["allow", 1102], ["identifying", 1108], ["pitfalls", 1120], ["in", 1129], ["the", 1132], ["data", 1136], ["analysis", 1141], [".", 1149]]}
{"context": "To investigate whether body mass index (BMI), as a proxy for body fat, influences rheumatoid arthritis (RA) disease activity in a gender-specific manner. Consecutive patients with RA were enrolled from 25 countries into the QUEST-RA program between 2005 and 2008. Clinical and demographic data were collected by treating rheumatologists and by patient self-report. Distributions of Disease Activity Scores (DAS28), BMI, age, and disease duration were assessed for each country and for the entire dataset; mean values between genders were compared using Student's t-tests. An association between BMI and DAS28 was investigated using linear regression, adjusting for age, disease duration and country. A total of 5,161 RA patients (4,082 women and 1,079 men) were included in the analyses. Overall, women were younger, had longer disease duration, and higher DAS28 scores than men, but BMI was similar between genders. The mean DAS28 scores increased with increasing BMI from normal to overweight and obese, among women, whereas the opposite trend was observed among men. Regression results showed BMI (continuous or categorical) to be associated with DAS28. Compared to the normal BMI range, being obese was associated with a larger difference in mean DAS28 (0.23, 95% CI: 0.11, 0.34) than being overweight (0.12, 95% CI: 0.03, 0.21); being underweight was not associated with disease activity. These associations were more pronounced among women, and were not explained by any single component of the DAS28. BMI appears to be associated with RA disease activity in women, but not in men.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "caa2671c22184059b24fc1b2ad609ea4", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[189, 189], [298, 298], [150, 150], [137, 137], [274, 274]], "char_spans": [[1012, 1016], [1565, 1569], [797, 801], [736, 740], [1440, 1444]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["body", 23], ["mass", 28], ["index", 33], ["(", 39], ["BMI", 40], [")", 43], [",", 44], ["as", 46], ["a", 49], ["proxy", 51], ["for", 57], ["body", 61], ["fat", 66], [",", 69], ["influences", 71], ["rheumatoid", 82], ["arthritis", 93], ["(", 103], ["RA", 104], [")", 106], ["disease", 108], ["activity", 116], ["in", 125], ["a", 128], ["gender", 130], ["-", 136], ["specific", 137], ["manner", 146], [".", 152], ["Consecutive", 154], ["patients", 166], ["with", 175], ["RA", 180], ["were", 183], ["enrolled", 188], ["from", 197], ["25", 202], ["countries", 205], ["into", 215], ["the", 220], ["QUEST", 224], ["-", 229], ["RA", 230], ["program", 233], ["between", 241], ["2005", 249], ["and", 254], ["2008", 258], [".", 262], ["Clinical", 264], ["and", 273], ["demographic", 277], ["data", 289], ["were", 294], ["collected", 299], ["by", 309], ["treating", 312], ["rheumatologists", 321], ["and", 337], ["by", 341], ["patient", 344], ["self", 352], ["-", 356], ["report", 357], [".", 363], ["Distributions", 365], ["of", 379], ["Disease", 382], ["Activity", 390], ["Scores", 399], ["(", 406], ["DAS28", 407], [")", 412], [",", 413], ["BMI", 415], [",", 418], ["age", 420], [",", 423], ["and", 425], ["disease", 429], ["duration", 437], ["were", 446], ["assessed", 451], ["for", 460], ["each", 464], ["country", 469], ["and", 477], ["for", 481], ["the", 485], ["entire", 489], ["dataset", 496], [";", 503], ["mean", 505], ["values", 510], ["between", 517], ["genders", 525], ["were", 533], ["compared", 538], ["using", 547], ["Student", 553], ["'s", 560], ["t", 563], ["-", 564], ["tests", 565], [".", 570], ["An", 572], ["association", 575], ["between", 587], ["BMI", 595], ["and", 599], ["DAS28", 603], ["was", 609], ["investigated", 613], ["using", 626], ["linear", 632], ["regression", 639], [",", 649], ["adjusting", 651], ["for", 661], ["age", 665], [",", 668], ["disease", 670], ["duration", 678], ["and", 687], ["country", 691], [".", 698], ["A", 700], ["total", 702], ["of", 708], ["5,161", 711], ["RA", 717], ["patients", 720], ["(", 729], ["4,082", 730], ["women", 736], ["and", 742], ["1,079", 746], ["men", 752], [")", 755], ["were", 757], ["included", 762], ["in", 771], ["the", 774], ["analyses", 778], [".", 786], ["Overall", 788], [",", 795], ["women", 797], ["were", 803], ["younger", 808], [",", 815], ["had", 817], ["longer", 821], ["disease", 828], ["duration", 836], [",", 844], ["and", 846], ["higher", 850], ["DAS28", 857], ["scores", 863], ["than", 870], ["men", 875], [",", 878], ["but", 880], ["BMI", 884], ["was", 888], ["similar", 892], ["between", 900], ["genders", 908], [".", 915], ["The", 917], ["mean", 921], ["DAS28", 926], ["scores", 932], ["increased", 939], ["with", 949], ["increasing", 954], ["BMI", 965], ["from", 969], ["normal", 974], ["to", 981], ["overweight", 984], ["and", 995], ["obese", 999], [",", 1004], ["among", 1006], ["women", 1012], [",", 1017], ["whereas", 1019], ["the", 1027], ["opposite", 1031], ["trend", 1040], ["was", 1046], ["observed", 1050], ["among", 1059], ["men", 1065], [".", 1068], ["Regression", 1070], ["results", 1081], ["showed", 1089], ["BMI", 1096], ["(", 1100], ["continuous", 1101], ["or", 1112], ["categorical", 1115], [")", 1126], ["to", 1128], ["be", 1131], ["associated", 1134], ["with", 1145], ["DAS28", 1150], [".", 1155], ["Compared", 1157], ["to", 1166], ["the", 1169], ["normal", 1173], ["BMI", 1180], ["range", 1184], [",", 1189], ["being", 1191], ["obese", 1197], ["was", 1203], ["associated", 1207], ["with", 1218], ["a", 1223], ["larger", 1225], ["difference", 1232], ["in", 1243], ["mean", 1246], ["DAS28", 1251], ["(", 1257], ["0.23", 1258], [",", 1262], ["95", 1264], ["%", 1266], ["CI", 1268], [":", 1270], ["0.11", 1272], [",", 1276], ["0.34", 1278], [")", 1282], ["than", 1284], ["being", 1289], ["overweight", 1295], ["(", 1306], ["0.12", 1307], [",", 1311], ["95", 1313], ["%", 1315], ["CI", 1317], [":", 1319], ["0.03", 1321], [",", 1325], ["0.21", 1327], [")", 1331], [";", 1332], ["being", 1334], ["underweight", 1340], ["was", 1352], ["not", 1356], ["associated", 1360], ["with", 1371], ["disease", 1376], ["activity", 1384], [".", 1392], ["These", 1394], ["associations", 1400], ["were", 1413], ["more", 1418], ["pronounced", 1423], ["among", 1434], ["women", 1440], [",", 1445], ["and", 1447], ["were", 1451], ["not", 1456], ["explained", 1460], ["by", 1470], ["any", 1473], ["single", 1477], ["component", 1484], ["of", 1494], ["the", 1497], ["DAS28", 1501], [".", 1506], ["BMI", 1508], ["appears", 1512], ["to", 1520], ["be", 1523], ["associated", 1526], ["with", 1537], ["RA", 1542], ["disease", 1545], ["activity", 1553], ["in", 1562], ["women", 1565], [",", 1570], ["but", 1572], ["not", 1576], ["in", 1580], ["men", 1583], [".", 1586]]}
{"context": "Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase with additional inhibitory effects on platelet derived growth factor (PDGF) receptors alpha and beta, and KIT. It has revolutionized the treatment of adult and pediatric patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and is also FDA-approved for KIT-positive advanced gastrointestinal tumor (GIST) and dermatofibrosarcoma protuberans. A wide spectrum of dermatologic toxicities has been associated with this agent, among which a maculopapular rash is the most common event. In addition, a variety of pigmentary abnormalities of the skin and mucosal surfaces have been reported. Hypopigmentation is a well-recognized adverse effect. In contrast, paradoxical hyperpigmentation has only rarely been documented. In this case report we describe imatinib-induced cutaneous hyperpigmentation and graying of hair occurring in the same patient with dermatofibrosarcoma protuberans treated with imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "631900f5ead84eacaf274c45701f595a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[27, 29]], "char_spans": [[172, 178]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["STI", 19], ["571", 23], [";", 26], ["Gleevec", 28], [";", 35], ["Novartis", 37], ["Pharmaceuticals", 46], [",", 61], ["Basel", 63], [",", 68], ["Switzerland", 70], [")", 81], ["is", 83], ["an", 86], ["orally", 89], ["available", 96], ["tyrosine", 106], ["kinase", 115], ["inhibitor", 122], ["that", 132], ["targets", 137], ["a", 145], ["constitutively", 147], ["activated", 162], ["BCR", 172], ["-", 175], ["ABL", 176], ["tyrosine", 180], ["kinase", 189], ["with", 196], ["additional", 201], ["inhibitory", 212], ["effects", 223], ["on", 231], ["platelet", 234], ["derived", 243], ["growth", 251], ["factor", 258], ["(", 265], ["PDGF", 266], [")", 270], ["receptors", 272], ["alpha", 282], ["and", 288], ["beta", 292], [",", 296], ["and", 298], ["KIT", 302], [".", 305], ["It", 307], ["has", 310], ["revolutionized", 314], ["the", 329], ["treatment", 333], ["of", 343], ["adult", 346], ["and", 352], ["pediatric", 356], ["patients", 366], ["with", 375], ["Philadelphia", 380], ["chromosome", 393], ["positive", 404], ["chronic", 413], ["myelogenous", 421], ["leukemia", 433], ["(", 442], ["CML", 443], [")", 446], ["and", 448], ["is", 452], ["also", 455], ["FDA", 460], ["-", 463], ["approved", 464], ["for", 473], ["KIT", 477], ["-", 480], ["positive", 481], ["advanced", 490], ["gastrointestinal", 499], ["tumor", 516], ["(", 522], ["GIST", 523], [")", 527], ["and", 529], ["dermatofibrosarcoma", 533], ["protuberans", 553], [".", 564], ["A", 566], ["wide", 568], ["spectrum", 573], ["of", 582], ["dermatologic", 585], ["toxicities", 598], ["has", 609], ["been", 613], ["associated", 618], ["with", 629], ["this", 634], ["agent", 639], [",", 644], ["among", 646], ["which", 652], ["a", 658], ["maculopapular", 660], ["rash", 674], ["is", 679], ["the", 682], ["most", 686], ["common", 691], ["event", 698], [".", 703], ["In", 705], ["addition", 708], [",", 716], ["a", 718], ["variety", 720], ["of", 728], ["pigmentary", 731], ["abnormalities", 742], ["of", 756], ["the", 759], ["skin", 763], ["and", 768], ["mucosal", 772], ["surfaces", 780], ["have", 789], ["been", 794], ["reported", 799], [".", 807], ["Hypopigmentation", 809], ["is", 826], ["a", 829], ["well", 831], ["-", 835], ["recognized", 836], ["adverse", 847], ["effect", 855], [".", 861], ["In", 863], ["contrast", 866], [",", 874], ["paradoxical", 876], ["hyperpigmentation", 888], ["has", 906], ["only", 910], ["rarely", 915], ["been", 922], ["documented", 927], [".", 937], ["In", 939], ["this", 942], ["case", 947], ["report", 952], ["we", 959], ["describe", 962], ["imatinib", 971], ["-", 979], ["induced", 980], ["cutaneous", 988], ["hyperpigmentation", 998], ["and", 1016], ["graying", 1020], ["of", 1028], ["hair", 1031], ["occurring", 1036], ["in", 1046], ["the", 1049], ["same", 1053], ["patient", 1058], ["with", 1066], ["dermatofibrosarcoma", 1071], ["protuberans", 1091], ["treated", 1103], ["with", 1111], ["imatinib", 1116], [".", 1124]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "Restless legs syndrome/Willis Ekbom disease (RLS/WED) has been recognized as a significant medical disorder since the 17th century. It was studied mostly in the last 50 years in relation to increasing interest in sleep medicine and health-related quality of life. This led to recognition that the disease is not well characterized as restless feelings in the legs. These symptoms are reported in many situations, but the subjective experience of RLS/WED patients differs from that experienced by others. Thus a new name has been introduced that avoids problems of symptom definition of a disease by naming it after those who first characterized it, i.e. 'Willis Ekbom disease'. This article emphasizes the importance of RLS/WED for psychiatry. The disease carries significant increased risk for depression and anxiety disorders. Treatment requires consideration of these co-morbid disorders. RLS/WED can exacerbate or even engender psychiatric disease, so treatment of psychiatric disease should also include consideration of RLS/WED. The need for attention to RLS/WED is particularly significant for depression. Most anti-depressants exacerbate or can even engender RLS/WED. Thus this article seeks to introduce RLS/WED in relation to psychiatric practice. It presents the RLS/WED disease, its overlap with psychiatry and the current treatment options.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "289d6353e4064a62a58db9f9192b3eff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["has", 54], ["been", 58], ["recognized", 63], ["as", 74], ["a", 77], ["significant", 79], ["medical", 91], ["disorder", 99], ["since", 108], ["the", 114], ["17th", 118], ["century", 123], [".", 130], ["It", 132], ["was", 135], ["studied", 139], ["mostly", 147], ["in", 154], ["the", 157], ["last", 161], ["50", 166], ["years", 169], ["in", 175], ["relation", 178], ["to", 187], ["increasing", 190], ["interest", 201], ["in", 210], ["sleep", 213], ["medicine", 219], ["and", 228], ["health", 232], ["-", 238], ["related", 239], ["quality", 247], ["of", 255], ["life", 258], [".", 262], ["This", 264], ["led", 269], ["to", 273], ["recognition", 276], ["that", 288], ["the", 293], ["disease", 297], ["is", 305], ["not", 308], ["well", 312], ["characterized", 317], ["as", 331], ["restless", 334], ["feelings", 343], ["in", 352], ["the", 355], ["legs", 359], [".", 363], ["These", 365], ["symptoms", 371], ["are", 380], ["reported", 384], ["in", 393], ["many", 396], ["situations", 401], [",", 411], ["but", 413], ["the", 417], ["subjective", 421], ["experience", 432], ["of", 443], ["RLS", 446], ["/", 449], ["WED", 450], ["patients", 454], ["differs", 463], ["from", 471], ["that", 476], ["experienced", 481], ["by", 493], ["others", 496], [".", 502], ["Thus", 504], ["a", 509], ["new", 511], ["name", 515], ["has", 520], ["been", 524], ["introduced", 529], ["that", 540], ["avoids", 545], ["problems", 552], ["of", 561], ["symptom", 564], ["definition", 572], ["of", 583], ["a", 586], ["disease", 588], ["by", 596], ["naming", 599], ["it", 606], ["after", 609], ["those", 615], ["who", 621], ["first", 625], ["characterized", 631], ["it", 645], [",", 647], ["i.e.", 649], ["'", 654], ["Willis", 655], ["Ekbom", 662], ["disease", 668], ["'", 675], [".", 676], ["This", 678], ["article", 683], ["emphasizes", 691], ["the", 702], ["importance", 706], ["of", 717], ["RLS", 720], ["/", 723], ["WED", 724], ["for", 728], ["psychiatry", 732], [".", 742], ["The", 744], ["disease", 748], ["carries", 756], ["significant", 764], ["increased", 776], ["risk", 786], ["for", 791], ["depression", 795], ["and", 806], ["anxiety", 810], ["disorders", 818], [".", 827], ["Treatment", 829], ["requires", 839], ["consideration", 848], ["of", 862], ["these", 865], ["co", 871], ["-", 873], ["morbid", 874], ["disorders", 881], [".", 890], ["RLS", 892], ["/", 895], ["WED", 896], ["can", 900], ["exacerbate", 904], ["or", 915], ["even", 918], ["engender", 923], ["psychiatric", 932], ["disease", 944], [",", 951], ["so", 953], ["treatment", 956], ["of", 966], ["psychiatric", 969], ["disease", 981], ["should", 989], ["also", 996], ["include", 1001], ["consideration", 1009], ["of", 1023], ["RLS", 1026], ["/", 1029], ["WED", 1030], [".", 1033], ["The", 1035], ["need", 1039], ["for", 1044], ["attention", 1048], ["to", 1058], ["RLS", 1061], ["/", 1064], ["WED", 1065], ["is", 1069], ["particularly", 1072], ["significant", 1085], ["for", 1097], ["depression", 1101], [".", 1111], ["Most", 1113], ["anti", 1118], ["-", 1122], ["depressants", 1123], ["exacerbate", 1135], ["or", 1146], ["can", 1149], ["even", 1153], ["engender", 1158], ["RLS", 1167], ["/", 1170], ["WED", 1171], [".", 1174], ["Thus", 1176], ["this", 1181], ["article", 1186], ["seeks", 1194], ["to", 1200], ["introduce", 1203], ["RLS", 1213], ["/", 1216], ["WED", 1217], ["in", 1221], ["relation", 1224], ["to", 1233], ["psychiatric", 1236], ["practice", 1248], [".", 1256], ["It", 1258], ["presents", 1261], ["the", 1270], ["RLS", 1274], ["/", 1277], ["WED", 1278], ["disease", 1282], [",", 1289], ["its", 1291], ["overlap", 1295], ["with", 1303], ["psychiatry", 1308], ["and", 1319], ["the", 1323], ["current", 1327], ["treatment", 1335], ["options", 1345], [".", 1352]]}
{"context": "Mowat-Wilson syndrome is a genetic disease caused by heterozygous mutations or deletions of the zinc finger E-box-binding homeobox 2 (ZEB2) gene. The syndrome is characterized by typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, agenesis of the corpus callosum, and eye defects. The prevalence of Mowat-Wilson syndrome is currently unknown, but it seems that Mowat-Wilson syndrome is underdiagnosed, particularly in patients without Hirschsprung disease. We report here the first Egyptian case of Mowat-Wilson syndrome who was conceived by intracytoplasmic sperm injection. The patient manifested bilateral sensorineural hearing loss--a new feature not previously reported in cases of Mowat-Wilson syndrome. This report describes the first Egyptian patient of Mowat-Wilson syndrome who was conceived after intracytoplasmic sperm injection, and provides a new evidence for the inclusion of deafness among the congenital defects of the syndrome.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "c3272be6bdea40c9ac22dfe5337dc311", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[26, 26]], "char_spans": [[134, 137]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["disease", 35], ["caused", 43], ["by", 50], ["heterozygous", 53], ["mutations", 66], ["or", 76], ["deletions", 79], ["of", 89], ["the", 92], ["zinc", 96], ["finger", 101], ["E", 108], ["-", 109], ["box", 110], ["-", 113], ["binding", 114], ["homeobox", 122], ["2", 131], ["(", 133], ["ZEB2", 134], [")", 138], ["gene", 140], [".", 144], ["The", 146], ["syndrome", 150], ["is", 159], ["characterized", 162], ["by", 176], ["typical", 179], ["facial", 187], ["features", 194], [",", 202], ["moderate", 204], ["-", 212], ["to", 213], ["-", 215], ["severe", 216], ["mental", 223], ["retardation", 230], [",", 241], ["epilepsy", 243], ["and", 252], ["variable", 256], ["congenital", 265], ["malformations", 276], [",", 289], ["including", 291], ["Hirschsprung", 301], ["disease", 314], [",", 321], ["genital", 323], ["anomalies", 331], [",", 340], ["congenital", 342], ["heart", 353], ["disease", 359], [",", 366], ["agenesis", 368], ["of", 377], ["the", 380], ["corpus", 384], ["callosum", 391], [",", 399], ["and", 401], ["eye", 405], ["defects", 409], [".", 416], ["The", 418], ["prevalence", 422], ["of", 433], ["Mowat", 436], ["-", 441], ["Wilson", 442], ["syndrome", 449], ["is", 458], ["currently", 461], ["unknown", 471], [",", 478], ["but", 480], ["it", 484], ["seems", 487], ["that", 493], ["Mowat", 498], ["-", 503], ["Wilson", 504], ["syndrome", 511], ["is", 520], ["underdiagnosed", 523], [",", 537], ["particularly", 539], ["in", 552], ["patients", 555], ["without", 564], ["Hirschsprung", 572], ["disease", 585], [".", 592], ["We", 594], ["report", 597], ["here", 604], ["the", 609], ["first", 613], ["Egyptian", 619], ["case", 628], ["of", 633], ["Mowat", 636], ["-", 641], ["Wilson", 642], ["syndrome", 649], ["who", 658], ["was", 662], ["conceived", 666], ["by", 676], ["intracytoplasmic", 679], ["sperm", 696], ["injection", 702], [".", 711], ["The", 713], ["patient", 717], ["manifested", 725], ["bilateral", 736], ["sensorineural", 746], ["hearing", 760], ["loss", 768], ["--", 772], ["a", 774], ["new", 776], ["feature", 780], ["not", 788], ["previously", 792], ["reported", 803], ["in", 812], ["cases", 815], ["of", 821], ["Mowat", 824], ["-", 829], ["Wilson", 830], ["syndrome", 837], [".", 845], ["This", 847], ["report", 852], ["describes", 859], ["the", 869], ["first", 873], ["Egyptian", 879], ["patient", 888], ["of", 896], ["Mowat", 899], ["-", 904], ["Wilson", 905], ["syndrome", 912], ["who", 921], ["was", 925], ["conceived", 929], ["after", 939], ["intracytoplasmic", 945], ["sperm", 962], ["injection", 968], [",", 977], ["and", 979], ["provides", 983], ["a", 992], ["new", 994], ["evidence", 998], ["for", 1007], ["the", 1011], ["inclusion", 1015], ["of", 1025], ["deafness", 1028], ["among", 1037], ["the", 1043], ["congenital", 1047], ["defects", 1058], ["of", 1066], ["the", 1069], ["syndrome", 1073], [".", 1081]]}
{"context": "Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family. The nerve growth factor antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA pathway in pain. As an alternative modality, small-molecule inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications. This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biological targets. Additional patents have been reviewed where Trk is not the main kinase of interest but in which high Trk potency is observed and the chemical matter is particularly noteworthy. Patents pre-dating this period have been reviewed previously. Scifinder and Google were used to find relevant patents and clinical information using Trk or Tropomyosin as the search term. Considerable recent progress has been made in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clinical evaluation. Inhibitors of both active and inactive conformations of the Trks as well as peripherally restricted molecules have been identified. Furthermore, TrkA-selective allosteric inhibitors have recently been disclosed, which enables the biology of this isoform to be probed. The recent identification of a TrkA gene fusion in a subset of lung cancer patients will increase further the attraction of Trk inhibition to the pharmaceutical industry.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "6f76097048934cc28e54c79c8ca57345", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[24, 26]], "char_spans": [[145, 163]]}]}], "context_tokens": [["Tropomyosin", 0], ["receptor", 12], ["kinases", 21], ["(", 29], ["Trks", 30], [")", 34], ["are", 36], ["a", 40], ["family", 42], ["of", 49], ["three", 52], ["similar", 58], ["tyrosine", 66], ["kinases", 75], ["activated", 83], ["by", 93], ["peptide", 96], ["hormones", 104], ["of", 113], ["the", 116], ["neurotrophin", 120], ["family", 133], [".", 139], ["The", 141], ["nerve", 145], ["growth", 151], ["factor", 158], ["antibody", 165], ["tanezumab", 174], ["has", 184], ["provided", 188], ["clinical", 197], ["proof", 206], ["of", 212], ["concept", 215], ["for", 223], ["inhibition", 227], ["of", 238], ["the", 241], ["TrkA", 245], ["pathway", 250], ["in", 258], ["pain", 261], [".", 265], ["As", 267], ["an", 270], ["alternative", 273], ["modality", 285], [",", 293], ["small", 295], ["-", 300], ["molecule", 301], ["inhibitors", 310], ["of", 321], ["the", 324], ["Trks", 328], ["have", 333], ["been", 338], ["pursued", 343], ["in", 351], ["recent", 354], ["years", 361], ["to", 367], ["probe", 370], ["the", 376], ["role", 380], ["of", 385], ["these", 388], ["neurotrophin", 394], ["pathways", 407], ["in", 416], ["pain", 419], [",", 423], ["cancer", 425], ["and", 432], ["other", 436], ["indications", 442], [".", 453], ["This", 455], ["paper", 460], ["reviews", 466], ["the", 474], ["patent", 478], ["literature", 485], ["between", 496], ["mid-2009", 504], ["and", 513], ["2013", 517], [",", 521], ["claiming", 523], ["inhibitors", 532], ["of", 543], ["Trk", 546], ["family", 550], ["members", 557], ["as", 565], ["the", 568], ["primary", 572], ["biological", 580], ["targets", 591], [".", 598], ["Additional", 600], ["patents", 611], ["have", 619], ["been", 624], ["reviewed", 629], ["where", 638], ["Trk", 644], ["is", 648], ["not", 651], ["the", 655], ["main", 659], ["kinase", 664], ["of", 671], ["interest", 674], ["but", 683], ["in", 687], ["which", 690], ["high", 696], ["Trk", 701], ["potency", 705], ["is", 713], ["observed", 716], ["and", 725], ["the", 729], ["chemical", 733], ["matter", 742], ["is", 749], ["particularly", 752], ["noteworthy", 765], [".", 775], ["Patents", 777], ["pre", 785], ["-", 788], ["dating", 789], ["this", 796], ["period", 801], ["have", 808], ["been", 813], ["reviewed", 818], ["previously", 827], [".", 837], ["Scifinder", 839], ["and", 849], ["Google", 853], ["were", 860], ["used", 865], ["to", 870], ["find", 873], ["relevant", 878], ["patents", 887], ["and", 895], ["clinical", 899], ["information", 908], ["using", 920], ["Trk", 926], ["or", 930], ["Tropomyosin", 933], ["as", 945], ["the", 948], ["search", 952], ["term", 959], [".", 963], ["Considerable", 965], ["recent", 978], ["progress", 985], ["has", 994], ["been", 998], ["made", 1003], ["in", 1008], ["the", 1011], ["identification", 1015], ["of", 1030], ["selective", 1033], ["pan", 1043], ["Trk", 1047], ["inhibitors", 1051], ["with", 1062], ["pharmacodynamic", 1067], ["and", 1083], ["pharmacokinetic", 1087], ["properties", 1103], ["appropriate", 1114], ["for", 1126], ["clinical", 1130], ["evaluation", 1139], [".", 1149], ["Inhibitors", 1151], ["of", 1162], ["both", 1165], ["active", 1170], ["and", 1177], ["inactive", 1181], ["conformations", 1190], ["of", 1204], ["the", 1207], ["Trks", 1211], ["as", 1216], ["well", 1219], ["as", 1224], ["peripherally", 1227], ["restricted", 1240], ["molecules", 1251], ["have", 1261], ["been", 1266], ["identified", 1271], [".", 1281], ["Furthermore", 1283], [",", 1294], ["TrkA", 1296], ["-", 1300], ["selective", 1301], ["allosteric", 1311], ["inhibitors", 1322], ["have", 1333], ["recently", 1338], ["been", 1347], ["disclosed", 1352], [",", 1361], ["which", 1363], ["enables", 1369], ["the", 1377], ["biology", 1381], ["of", 1389], ["this", 1392], ["isoform", 1397], ["to", 1405], ["be", 1408], ["probed", 1411], [".", 1417], ["The", 1419], ["recent", 1423], ["identification", 1430], ["of", 1445], ["a", 1448], ["TrkA", 1450], ["gene", 1455], ["fusion", 1460], ["in", 1467], ["a", 1470], ["subset", 1472], ["of", 1479], ["lung", 1482], ["cancer", 1487], ["patients", 1494], ["will", 1503], ["increase", 1508], ["further", 1517], ["the", 1525], ["attraction", 1529], ["of", 1540], ["Trk", 1543], ["inhibition", 1547], ["to", 1558], ["the", 1561], ["pharmaceutical", 1565], ["industry", 1580], [".", 1588]]}
